Saturday, October 21, 2023
Meilleur Technologies, Inc. has announced a collaborative research agreement with the Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4) to investigate the use of Meilleur’s investigational imaging agent, [F-18]NAV-4694, in Positron Emission Tomography (PET) scans for assessing amyloid plaque status in the brain. Amyloid plaques are a characteristic feature of various neurodegenerative diseases, including Alzheimer's Disease (AD).
The primary goal of this collaboration is to utilize [F-18]NAV-4694 as an imaging biomarker in ADNI4's research on neurodegenerative diseases. The partners will employ [F-18]NAV-4694 imaging to support ADNI4's mission to gain a deeper understanding of AD, ultimately improving the diagnosis and treatment of this debilitating disease.
Meilleur Technologies, Inc., emphasized the company's commitment to advancing technologies with the potential to combat neurodegenerative diseases. He noted that NAV4694 possesses unique characteristics that can contribute to the development of current and future therapeutic approaches for neurodegenerative diseases. Meilleur is excited to include ADNI4 in their growing network of partners in the pharmaceutical and academic sectors, along with globally recognized production facilities. The ultimate aim is to make this innovative investigational imaging agent more widely accessible to the broader scientific community.
ADNI, also expressed his satisfaction with the addition of NAV4694 to the range of tracers used in ADNI4's research. He highlighted the exciting advancements in Alzheimer's research and emphasized the potential of tools like NAV4694 in improving our understanding of future therapy and intervention possibilities.